Focal Cerebral Arteriopathy Steroid Trial
NCT06040255 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2026-01-26
Summary
This comparative effectiveness trial (CET) in children with suspected focal cerebral arteriopathy (FCA) presenting with arterial ischemic stroke (AIS) or transient ischemic attack (TIA) will compare the use of early corticosteroid treatment (Arm A) versus delayed/no corticosteroid treatment (Arm B). Delayed corticosteroid treatment is given only for those demonstrating disease progression and is initiated as soon as the progression is detected (at any time after randomization). All participants will also receive standard of care therapy (aspirin and supportive care). Sites will randomize participants 1:1 to Arm A or B. Participants will be enrolled and randomized as soon as possible after their stroke/TIA up until 96 hours following the initial stroke/TIA event.
Conditions
- Pediatric Stroke
- Arteriopathy
- Arterial Ischemic Stroke
Interventions
- DRUG
-
methylprednisolone, prednisolone, prednisone
Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
Sponsors & Collaborators
-
University of Cincinnati
collaborator OTHER -
Medical University of South Carolina
collaborator OTHER -
M.D. Anderson Cancer Center
collaborator OTHER -
University of Colorado, Denver
collaborator OTHER -
University of Iowa
collaborator OTHER -
National Institute of Neurological Disorders and Stroke (NINDS)
collaborator NIH - collaborator OTHER
-
University of California, San Francisco
lead OTHER
Principal Investigators
-
Heather J Fullerton, MD, MAS · University of California, San Francisco
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-01
- Primary Completion
- 2029-07-31
- Completion
- 2030-01-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months
NCT06841978 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Thrombolysis of Urokinase for Minor Stroke
NCT04420351 ·Status: COMPLETED ·Phase: PHASE3
-
Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II
NCT02560935 ·Status: COMPLETED ·Phase: PHASE3
-
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
NCT06053021 ·Status: RECRUITING ·Phase: NA
-
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke
NCT04280003 ·Status: UNKNOWN ·Phase: PHASE2
-
Sickle Cell Disease - Stroke Prevention in Nigeria Trial
NCT01801423 ·Status: COMPLETED ·Phase: NA
-
Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke
NCT03552354 ·Status: COMPLETED ·Phase: PHASE4
-
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
NCT02953405 ·Status: UNKNOWN
-
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
NCT02549846 ·Status: COMPLETED ·Phase: PHASE4
-
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
NCT05429476 ·Status: COMPLETED ·Phase: PHASE3
-
Endovascular Therapy for Acute Ischemic Stroke Trial
NCT02350283 ·Status: COMPLETED ·Phase: PHASE3
-
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250 ·Status: RECRUITING ·Phase: NA
-
Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion
NCT07141303 ·Status: RECRUITING ·Phase: PHASE3
-
The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial
NCT01020851 ·Status: COMPLETED ·Phase: NA
-
FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
NCT06409364 ·Status: RECRUITING ·Phase: PHASE2
-
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
NCT06010628 ·Status: RECRUITING ·Phase: PHASE4
-
A Proof of Concept Study to Evaluate CN-105 in ICH Patients
NCT03168581 ·Status: COMPLETED ·Phase: PHASE2
-
THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)
NCT02002325 ·Status: UNKNOWN ·Phase: PHASE3
-
A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
NCT02398656 ·Status: COMPLETED ·Phase: PHASE3
-
Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study
NCT06785740 ·Status: RECRUITING
-
Clinical Trial Study About Human Adipose-Derived Stem Cells in the Stroke
NCT02813512 ·Status: COMPLETED ·Phase: PHASE1
-
Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke
NCT06870448 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
NCT03192215 ·Status: TERMINATED ·Phase: PHASE3
-
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
NCT06329635 ·Status: RECRUITING ·Phase: NA